Lumos Diagnostics Holdings Limited (LDXHF) Shareholder/Analyst Call Transcript

Amelia Stephens

Thank you for joining us today for this outpatient- focused webinar hosted by Lumos Diagnostics as an Antibiotic Stewardship Sponsor of the Urgent Care Association. Today’s session will also feature real-world insights from WellStreet Urgent Care, one of the nation’s leading urgent care organizations.

My name is Amelia Stephens, and I’m the Global Marketing Consultant for Lumos Diagnostics. I’ll be moderating today’s session, welcome.

Today’s webinar is titled reducing diagnostic uncertainty, Rapid evidence-based antibiotics stewardship and outpatient care. Today’s discussion will focus on stewardship solutions for outpatient settings. Particularly during peak respiratory season when overlapping symptoms are heightened and patient volume surge.

Next slide, please, image in. We’re also joined today by Annie Bell, Vice President of Medical Affairs at Lumos Diagnostics. Annie leads clinical strategy and clinical research for Lumos’ rapid diagnostic technologies and has contributed to multiple peer-reviewed clinical studies on FebriDx.

With expertise in clinical research, host response biomarkers, infectious disease, respiratory diagnostics and antimicrobial stewardship and he works closely with clinicians to evaluate and implement tools that improve diagnostic accuracy and patient outcomes.

Today, Annie will walk us through the clinical evidence behind FebriDx and explain how rapid diagnostics can support evidence-based antibiotic decision-making during the initial patient visit.

We’re also joined today by Dr. Brian Bobb, Senior Medical Officer at WellStreet Urgent Care, one of the nation’s leading urgent care networks. In this role, Dr. Bobb oversees quality improvement, provider and education and clinical pathway development across high-volume centers.

His work focuses on reducing unnecessary antibiotic use improving diagnostic confidence and enhancing care consistency, especially during high-volume seasons. Today, Dr. Bobb will share real-world insights from WellStreet’s implementation of FebriDx, including how